TapImmune, Inc. (NASDAQ: TPIV) announced today it has successfully completed a multi-gram scale-up and GMP manufacturing of a second clinical lot of TPIV 200, the company’s multi-epitope T-cell vaccine targeting folate receptor alpha.
52 Week Range
TapImmune, Inc. specializes in developing immunotherapies for a variety of cancers and infectious diseases designed to target tumors and metastatic disease. The company is currently conducting preclinical and clinical trials in breast and ovarian cancer to explore the promising commercial potential of its comprehensive approach to immunotherapy. Founded in 2006, TapImmune, Inc. is headquartered in Jacksonville, FL.
IR CONTACT DETAILS
50 N. Laura St. Suite 2500
Jacksonville, FL 32202